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Objective: Characterize the impact of a pharmacist-led 
diabetes self-management program on three key 
metabolic parameters: glycosylated hemoglobin (HbA1c), 
low-density lipoprotein cholesterol (LDL-C), and mean 
arterial blood pressure (MAP) among employee health 
program participants. 
Methods: A self-insured company in the Kansas City 
metropolitan area began offering a pharmacist-led 
diabetes self-management program to eligible company 
employees and their dependents in 2008. A retrospective 
pre-post analysis was conducted to determine if the 
program affected key metabolic parameters in participants 
by determining mean change after one year of 
participation.  
Results: Among 183 program participants, 65 participants 
met inclusion criteria. All three key metabolic parameters 
were significantly reduced from baseline to one year of 
program participation: HbA1c decreased from 8.1% to 
7.3% (p=0.007); LDL-C decreased from 108.3 mg/dL to 
96.4 mg/dL (p=0.009); and MAP decreased from 96.1 to 
92.3 mm Hg (p=0.005). 
Conclusions: The pharmacist-led diabetes self-
management program demonstrated significant reductions 
in HbA1c, LDL-C, and MAP from baseline to one year of 
program participation. Improvements were statistically 
significant and clinically relevant for each parameter. 
Previous studies indicate these reductions may cause 
reduced overall healthcare costs. 
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INTRODUCTION 
Chronic diseases, including diabetes, are a 
widespread health problem. Diabetes affects 
approximately 25.8 million Americans and ranks as 
the seventh leading cause of death in the United 
States.1 The impact of diabetes includes both 
physical complications and significant financial 
burdens. Adults with diabetes have a two to four 
times greater risk for stroke than those without 
diabetes, and are two to four times more likely to die 
from heart disease.1 Medical expenses for people 
with diabetes are more than two times higher than 
for those without diabetes.1 Employers bear the 
economic burden both directly through employer-
provided health insurance and indirectly through 
higher rates of sick days, disability, and injury. 
Employee wellness programs including pharmacist-
directed services may help reduce long-term 
complications and costs associated with diabetes.2 
Community pharmacists have provided diabetes 
disease state management services for over a 
decade. These services include pharmacist 
coaching, patient education, implementing 
evidence-based diabetes care guidelines, and 
teaching patient self-management strategies.2,3 
Prior studies indicate community-based diabetes 
management programs provide clinical 
improvement on glycosylated hemoglobin (HbA1c), 
low-density lipoprotein cholesterol (LDL-C), and 
blood pressure (BP).2,3 These previous analyses 
lack information regarding the provision of these 
programs in a local grocery store chain setting. 
Additionally, to our knowledge, most of the previous 
analyses included data from over 100 participants.2-
8 This study demonstrates that even with fewer than 
100 patients (n=65), pharmacists can make not only 
a statistically significant but also a clinically 
significant impact on diabetes management. 
Pharmacists in this setting are well positioned to 
help patients with diabetes achieve glycemic control 
and prevent long-term complications. 
The objective was to assess the impact of a 
pharmacist-led diabetes self-management program 
provided to insured individuals with diabetes in a 
local chain grocery store. Impact was defined as 
mean change from baseline to one year in three key 
metabolic parameters including HbA1c, LDL-C, and 
mean arterial blood pressure (MAP). 
 
METHODS  
This study was conducted at Balls Food Stores, a 
self-insured employer in the Kansas City 
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metropolitan area. The employer operates 27 
grocery stores with 20 pharmacies. The employer 
began offering a pharmacist-led diabetes self-
management program to eligible company 
employees and their dependents in 2008. Eligibility 
for the program was based on a Type 1 or Type 2 
diabetes diagnosis from medical claims data. 
Program participation incentives included: reduced 
health insurance premiums, a free blood glucose 
meter, reduced copays on lancets, waived copays 
for generic glucose-lowering agents, and 50% 
discounted copays on needles, syringes, pen 
needles, and brand name glucose-lowering agents.  
Employees and dependents who participated in the 
pharmacist-led diabetes self-management program 
enrolled voluntarily and completed a program 
participation agreement detailing program goals, 
patient responsibility, confidentiality, and right to 
withdraw from the program. Participants consented 
to release medical information, allowing 
pharmacists to correspond with patients’ providers. 
Providers were informed of their patient’s program 
participation and were encouraged to share their 
treatment goals with the pharmacists. 
The program consisted of one-on-one visits 
between the patient and an assigned clinical 
pharmacist averaging six 30-minute visits each 
year. Visits were scheduled on an individual basis to 
meet the needs of the patient and did not occur at 
rigidly defined intervals. During each visit, the 
pharmacist provided patient-specific education 
regarding numerous diabetes related topics 
including pathology, healthy lifestyle habits, 
medication use and adherence, progress toward 
appropriate therapeutic goals, and self-monitoring. 
Each visit also included a brief assessment to 
determine the patient’s level of understanding on 
the education topic. Clinical measurements such as 
blood pressure, blood sugar, and weight were also 
collected by the pharmacist during visits. Following 
each visit, the pharmacist corresponded with the 
patients’ provider via a faxed summary note that 
included subjective and objective findings, the 
education topic covered at the visit, and any 
recommended changes to drug therapy. The 
pharmacist made treatment recommendations 
based on clinical practice guidelines or referred 
patients to their provider for further assessment, 
laboratory tests, or other needs. The provider 
remained responsible for changes in medication 
therapy. 
The pharmacist-led diabetes self-management 
program focused on intense patient self-care 
education, frequent patient monitoring, goal 
planning, and structured patient accountability. The 
program curriculum was based on the American 
Pharmacists Association (APhA) Foundation’s 
psychometrically validated Patient Self-
Management Program (PSMP) for Diabetes that 
stemmed from the Asheville Project.4 Knowledge 
and skills assessments were utilized to coach 
patients toward optimal diabetes management. A 
performance checklist was utilized to assess 
ongoing self-management, which included 
preventative care measures consistent with 
diabetes care guidelines. All clinical pharmacists in 
the pharmacist-led diabetes self-management 
program were residency-trained and completed a 
diabetes certificate training program offered through 
APhA. 
This study was a retrospective pre-post analysis. 
Participants who enrolled in the pharmacist-led 
diabetes self-management program between 
November 1, 2008 and December 31, 2012 were 
eligible for inclusion if they were 18 years or older, 
had at least two documented program visits with a 
clinical pharmacist, and had both baseline and one 
year data for HbA1c, LDL-C, and MAP. Baseline 
was defined as three months prior to or one month 
following the first program visit with a clinical 
pharmacist. One year was defined as 10 to 14 
months following the first program visit with a 
clinical pharmacist. 
Following approval by the University of Kansas 
Human Subjects Committee, de-identified data were 
collected for general demographics and metabolic 
parameters from a web-based documentation 
system. Clinical values were collected from patients’ 
laboratory reports made available by providers and 
also from physical assessments completed by 
clinical pharmacists at each one-on-one visit.  
The clinical outcomes measured were the mean 
changes from baseline to one year for HbA1c, LDL-
C, and MAP among program participants. 
Previously, pharmacist-led diabetes self-
management publications individually evaluated 
systolic and diastolic BP as separate variables.2,4,7,8 
However, we chose to simply evaluate MAP in 
place of SBP and DBP for two reasons. First, MAP 
is an accurate composite assessment of BP, 
calculated by the equation: MAP=[(2 x 
diastolic)+systolic] / 3. Secondly, the statistical 
comparison of a composite measure of blood 
pressure, rather than its individual components, 
reduces the type I statistical error rate which may 
result from evaluation of multiple outcomes among 
the same cohort. Since the data was normally 
distributed, paired t tests were used to analyze the 
difference between baseline and one year mean 
changes for each of the three key metabolic 
parameters. The a priori alpha level of significance 
was reduced from p<0.05 to p<0.01 to reduce the 
risk of committing a type I error since three 
statistical comparisons were utilized. 
 
RESULTS  
A total of 183 patients participated in the 
pharmacist-led diabetes self-management program 
between 2008 and 2012. Of these patients, 118 
were excluded from analysis: three were less than 
18 years old, 25 did not participate for one year, and 
90 were missing baseline and/or one-year data. 
Therefore, 65 patients were included in the analysis. 
Demographics are summarized in Table 1. Of the 
65 patients, the majority were female with an 
average age of 54 years. 
At the end of one year, statistically significant 
improvements were found for program participants 
in HbA1c, LDL-C, and MAP (Table 2). Mean HbA1c 
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decreased 0.7% during program participation but 
remained above the American Diabetes Association 
(ADA) guideline goal of <7% at the end of one 
year.9 Mean LDL-C concentrations also decreased 
and were below the National Cholesterol Education 
Program Adult Treatment Panel III guideline goal of 
<100 mg/dL.10 BP reductions were also noted as 
MAP decreased 4.6 mmHg at the end of one year. 
The baseline MAP values reflect systolic and 
diastolic BP readings achieving the ADA guideline 
goal of <130/80 mm Hg, whereas the one year MAP 




This analysis shows that HbA1c concentrations, the 
primary metabolic parameter for diabetes, improved 
following one year of participation in the pharmacist-
led diabetes self-management program. Our study 
demonstrated a statistically and clinically significant 
reduction in HbA1c of 0.7%. This is consistent with 
data from the Diabetes Ten City Challenge and 
Project IMPACT: Diabetes which established a 
mean HbA1c decrease of 0.4% and 0.8% 
respectively after one year of participation in a 
pharmacist-managed program.2,10 Previous 
research established that any reduction in HbA1c 
correlates with a decreased risk of complications 
making the improvement demonstrated in this study 
clinically relevant.11 
Additionally, our study showed an 11.9 mg/dL LDL-
C reduction after one year, which is similar to the 
11.4 mg/dL reduction demonstrated in the 
PAMPERED study that also showed the benefit of 
collaborative diabetes management with a clinical 
pharmacist.13 If mean systolic and diastolic BP 
changes from the PSMP for Diabetes are used to 
calculate MAP, our study also demonstrated a 
similar impact on BP control by achieving a 4.6 mm 
Hg reduction compared to 3.2 mm Hg seen in the 
PSMP.4 
The primary focus of the pharmacist-led diabetes 
self-management program was to equip patients to 
better care for their chronic disease by partnering 
with them in the self-care process. Patients met 
regularly with their clinical pharmacist to have 
questions answered, learn self-management 
strategies, and be held accountable for meeting 
personal diabetes-related goals. Whenever 
possible, patients maintained visits with the same 
clinical pharmacist for the duration of their program 
participation.  
Collaboration between providers and the clinical 
pharmacists was another integral element in the 
program’s success. Providers were encouraged to 
share their treatment plan with the patient’s clinical 
pharmacist. Additionally, the clinical pharmacists 
faxed brief summary notes and recommendations 
after each visit to the patients’ provider.  
A study by Wagner et al. demonstrated overall 
health cost savings within one to two years with a 
persistent HbA1c reduction.14 Thus, our program 
may have resulted in total health care cost savings 
since a significant reduction was seen in HbA1c at 
the end of one year of participation. As a result of 
the clinical improvements associated with this 
program, another local self-insured employer has 
contracted with Balls Food Stores to incorporate this 
pharmacist-led diabetes self-management program 
into their health plan. 
Limitations of this study include: the observational 
nature lacking randomization or a control group and 
the small sample size (n=65). Also, this pharmacist-
led diabetes self-management program was offered 
as a voluntary health benefit so participants may be 
healthier and more motivated than those who 
declined to participate. Furthermore, economic and 
humanistic data has not been collected. Future 
studies should include assessment of economic and 
humanistic data to provide further support for 
employer-based collaborative diabetes 
management programs utilizing community 
pharmacists. Study duration was also a limitation 
since patients were only analyzed for their first year 
of program participation. Many participants 
continued the program so analysis of data beyond 
one year may be useful in determining the 
persistence of improvements seen. 
 
CONCLUSIONS 
Patients with diabetes who met one-on-one with a 
clinical pharmacist as part of an employer-
sponsored pharmacist-led diabetes self-
management program achieved significant 
improvements in HbA1c, LDL-C, and MAP at the 
end of one year compared to baseline data. 
Reductions in each of the three metabolic 
parameters were statistically and clinically 
significant, although HbA1c values remained above 
the ADA guideline goal following one year of 
program participation.9 Based on results from 
previous studies, these reductions are expected to 
correspond with a decline in projected total direct 
patient medical costs.2 
Table 1. Demographics of diabetes self-management 
program participants (n=65) 
Characteristic Baseline  
Mean Age, years (SD) 53.5 (9.2) 
Female, no. (%) 36 (55%) 
Tobacco Use, no. (%) 16 (25%) 
Mean Body Mass Index, kg/m2 (SD)  33.7 (7.1) 




One Year Value 
Mean (SD) 
Change from Baseline 
Mean (95%CI) 
pa 
HbA1c (%) 8.1 (2.4) 7.3 (1.4) -0.7 (0.2:1.2) 0.007 
LDL-C (mg/dL) 108.3 (36.4) 96.4 (27.6) -11.9 (3.1:20.7) 0.009 
MAP (mm Hg) 96.1 (13.0) 92.3 (12.2) -4.6 (1.8:7.5) 0.002 
Abbreviations used: CI, confidence interval; HbA1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein 
cholesterol; MAP, mean arterial blood pressure. 
a p-value determined by two-tailed t tests for paired data assessing the mean change with alpha set at <0.01. 
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IMPACTO SOBRE LOS PARÁMETROS 
METABÓLICOS CLAVE DE UN PROGRAMA DE 




Objetivo: Caracterizar el impacto de un programa 
farmacéutico de auto-manejo de la diabetes entre os 
empelados participantes en un programa de salud sobre 
tres parámetros metabólicos claves: hemoglobina 
glicosilada (HbA1c), colesterol de baja densidad (LDL-
C), and media de presión arterial (MAP). 
Métodos: Una empresa auto-asegurada del área 
metropolitana de Kansas City comenzó a ofrecer un 
programa farmacéutico de automanejo de la diabetes a 
trabajadores elegibles y sus familiares en 2008. Se realizó 
un análisis retrospectivo pre-post para determinar si el 
programa afectó a los parámetros metabólicos clave de 
los participantes determinando el cambio medio tras un 
años de participación. 
Resultados: De los 183 participantes del programa, 65 
cumplieron los criterios de inclusión. Los tres parámetros 
metabólicos clave se redujeron significativamente desde 
el inicio hasta un año de participación en el programa: 
HbA1c disminuyó de 8,1% a 7,3% (p=0,007); LDL-C 
disminuyó de 108,3 mg/dL a 96,4 mg/dL (p=0,009); y 
MAP disminuyó de 96,1 a 92,3 mm Hg (p=0,005). 
Concusiones: El programa farmacéutico de auto-manejo 
de la diabetes demostró reducciones significativas en 
HbA1c, LDL-C, y MAP entre su inicio y un año de 
participación. Las mejoras fueron estadísticamente 
significativas y clínicamente relevantes para todos los 
parámetros. Estudios previos indican que estas 
reducciones pueden producir ahorro de costes sanitarios 
generales. 
 
Palabras clave: Diabetes Mellitus; Servicios 
Farmacéuticos; Educación del Paciente como Asunto; 
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